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A B S T R A C T
Purpose
The GALLIUM study (ClinicalTrials.gov identiﬁer: NCT01332968) showed that obinutuzumab
(GA101; G) signiﬁcantly prolonged progression-free survival (PFS) in previously untreated patients
with follicular lymphoma relative to rituximab (R) when combined with cyclophosphamide (C),
doxorubicin, vincristine (V), and prednisone (P; CHOP); CVP; or bendamustine. This report focuses
on the impact of chemotherapy backbone on efﬁcacy and safety.
Patients and Methods
A total of 1,202 patients with previously untreated follicular lymphoma (grades 1 to 3a), advanced
disease (stage III or IV, or stage II with tumor diameter $ 7 cm), Eastern Cooperative Oncology
Group performance status 0 to 2, and requiring treatment were randomly assigned 1:1 to G
1,000 mg on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles or R 375 mg/m2 on day 1 of
each cycle, for six to eight cycles, depending on chemotherapy (allocated nonrandomly by center).
Responding patients received G or R for 2 years or until disease progression.
Results
Baseline Follicular Lymphoma International Prognostic Index risk, bulky disease, and comorbidities differed
by chemotherapy. After 41.1 months median follow-up, PFS (primary end point) was superior for G plus
chemotherapy (overall hazard ratio [HR], 0.68; 95%CI, 0.54 to0.87;P= .0016),with consistent results across
chemotherapy backbones (bendamustine: HR, 0.63; 95%CI, 0.46 to 0.88; CHOP:HR, 0.72; 95%CI, 0.48 to
1.10; CVP: HR, 0.79; 95% CI, 0.42 to 1.47). Grade 3 to 5 adverse events, notably cytopenias, were most
frequent with CHOP. Grade 3 to 5 infections and second neoplasms were most frequent with bend-
amustine, which was associated with marked and prolonged reductions in T-cell counts. Fatal events were
more frequent in patients treated with bendamustine, possibly reﬂecting differences in patient risk proﬁles.
Conclusion
Improved PFSwas observed for G plus chemotherapy for all three chemotherapy backbones. Safety
proﬁles differed, although comparisons are confounded by nonrandom chemotherapy allocation.
J Clin Oncol 36:2395-2404. © 2018 by American Society of Clinical Oncology. Creative Commons
Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-
nc-nd/4.0/
INTRODUCTION
Follicular lymphoma (FL) is the most common
type of indolent B-cell non-Hodgkin lymphoma
(NHL). In patients requiring therapy, the com-
bination of rituximab (R) with chemotherapy
followed by R maintenance is standard treat-
ment.1 The choice of chemotherapy backbone is
usually determined by local policies or algorithms,
themost commonly used being cyclophosphamide
(C), doxorubicin, vincristine (V), and prednisone
(P; CHOP), CVP, and bendamustine.2-5 Recent
results from two randomized phase III studies
in patients with indolent NHL showed that
progression-free survival (PFS) and/or event-free
survival was longer with R plus bendamustine
than with R plus CHOP or CVP as induction
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treatment.6,7 In the randomized FOLL-05 study, 8-year PFS rates
were higher for R-CHOP than for R-CVP.8
The GALLIUM study compared obinutuzumab (GA101; G)
plus chemotherapy with R plus chemotherapy followed by G or R
maintenance, respectively, and found that investigator-assessed
PFS in 1,202 previously untreated patients with FL was superior
with G plus chemotherapy (hazard ratio [HR], 0.66; 95% CI, 0.51
to 0.85; P = .0012), with a 3-year PFS proportion of 80% (control,
73%).9 The present analysis of GALLIUM describes the impact of
the three different chemotherapy backbones on the efﬁcacy and
safety of the two treatment arms in patients with FL, using an
updated data set (data cutoff: September 10, 2016).
PATIENTS AND METHODS
Study Design and Participants
GALLIUM is an open-label, randomized parallel-group study, de-
scribed in full previously.9 Eligible patients were age $ 18 years with
histologically documented, previously untreated grade 1 to 3a FL who had
stage III or IV disease (or stage II with bulky disease, ie, largest tumor
diameter $ 7 cm), Eastern Cooperative Oncology Group performance
status 0 to 2, adequate hematologic parameters, and with an indication for
treatment according to GELF (Groupe d’E´tude des Lymphomes Follicu-
laires) criteria.
GALLIUM was conducted in line with the International Conference
on Harmonization guidelines for Good Clinical Practice, and the protocol
was approved by the Ethics Committees of participating centers and
registered at ClinicalTrials.gov (ClinicalTrials.gov identiﬁer: NCT01332968).
All patients provided written informed consent.
Procedures
Patients were randomly assigned 1:1 to induction therapy with in-
travenous infusions of G 1,000 mg (days 1, 8, and 15 of cycle 1 and day 1 of
subsequent cycles) or R 375 mg/m2 (day 1 of each cycle) for six or eight
cycles, depending on chemotherapy. Treatment allocation was stratiﬁed by:
chemotherapy regimen, Follicular Lymphoma International Prognostic
Index (FLIPI) risk group, and geographic region. The chemotherapy
regimen—CHOP, CVP, or bendamustine—was selected by each center
before the study started, with all patients at a given center receiving the
same regimen; standard doses were used.9 Patients with complete or partial
response at the end of induction (EOI) receivedmaintenance with the same
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Fig 1. CONSORT diagram. Patient disposition in all patients with follicular lymphoma. AE, adverse event; FL, follicular lymphoma; G-chemotherapy, obinutuzumab plus
chemotherapy; ITT, intention-to-treat; R-chemotherapy, rituximab plus chemotherapy.
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antibody as received during induction (ie, G 1,000 mg or R 375 mg/m2)
every 2 months for 2 years or until disease progression if earlier.
Primary prophylaxis with colony-stimulating factors was recom-
mended for patients age $ 60 years and those with comorbidities and
strongly recommended during cycle 1 of G plus CHOP. Antibiotic and
antiviral prophylaxis was used according to guidelines of partici-
pating centers.
Tumor response was assessed using the 2007 revised response criteria
for NHL and Lugano 2014 criteria.10,11 T-cell counts in peripheral blood
were determined by ﬂow cytometry at a central laboratory, and immu-
noglobulin levels were assayed locally. Charlson Comorbidity Index (CCI)
for each patient was scored retrospectively on the basis of conditions
reported on the medical history page of the case report form.
Outcomes
The primary study end point was investigator-assessed PFS (time
from random assignment to the earliest of disease progression, relapse, or
death as a result of any cause) in patients with FL. PFS for patients without
disease progression, relapse, or death was censored at the time of the last
assessment. PFS was also assessed by an Independent Review Committee
(IRC). Response rates at EOI, with and without 18F-ﬂuorodeoxyglucose
positron emission tomography (PET) scan assessed by 2007 revised cri-
teria,10 were secondary end points. Other secondary end points included
overall survival (OS), time to next antilymphoma treatment (TTNALT),
and adverse events (AEs). Exploratory end points included EOI response
rate with 18F-ﬂuorodeoxyglucose PET scan assessed by IRC according to
Lugano 2014 criteria,11 counts of CD3+, CD4+, and CD8+ T cells in
peripheral blood, and immunoglobulin levels.
Statistical Analysis
The results reported in the primary paper9 were from a preplanned
efﬁcacy interim analysis (cutoff date: January 31, 2016). The data reported
herein are from an updated analysis with a data cutoff of September 10,
2016, providing an additional 6.6 months of median follow-up.
Efﬁcacy analysis was performed on all randomly assigned patients
with FL; safety analysis included all those who received any study
treatment. PFS and other time-to-event end points are described using
Kaplan-Meier estimates, and antibody treatment arms were compared
using log-rank tests, stratiﬁed by chemotherapy and FLIPI. Estimates of
the treatment effect were expressed as HRs on the basis of stratiﬁed Cox
proportional hazards models, including 95% CIs. Response rates were
compared using Cochran-Mantel-Haenszel tests. Subgroup analyses
were performed to assess treatment effect on PFS for selected baseline
parameters; heterogeneity of treatment effect across chemotherapy
regimens was assessed by interaction test, which is the recommended
statistical method,12 while acknowledging that this has limited power.
The study was not designed to assess differences in outcomes between
the nonrandomized chemotherapy groups or between G and R in any of
the individual chemotherapy groups, and so lacked statistical power to
detect whether any observed differences were signiﬁcant. Statistical ana-
lyses were performed with SAS v9.2 (SAS Institute, Cary, NC) and R v3.4.3
(R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics and Treatment
The intention-to-treat FL population comprised 1,202 patients
(601 per treatment arm); by chemotherapy group, patient numbers
were: bendamustine, 345; CHOP, 196; and CVP, 60 in the G arm and
341, 203, and 57, respectively, in the R arm. Patient disposition is
shown in Figure 1, and the distribution of enrolled patients by country
and by chemotherapy regimen is found in the Data Supplement.
Table 1. Baseline Patient Demographics and Disease Characteristics by Treatment Arm and by Chemotherapy Regimen (follicular lymphoma
intention-to-treat population)
Characteristic
Obinutuzumab Plus
Chemotherapy
(n = 601)
Rituximab Plus
Chemotherapy
(n = 601)
Bendamustine
(n = 686)
CHOP
(n = 399)
CVP
(n = 117)
Age, years 60 (26-88) 58 (23-85) 60 (23-88) 57 (31-85) 59 (32-85)
Age $ 70 97 (16) 106 (18) 122 (18) 56 (14) 25 (21)
Age $ 80 11 (2) 19 (3) 23 (3) 3 (1) 4 (3)
Male 283 (47) 280 (47) 332 (48) 177 (44) 54 (46)
Ann Arbor stage at diagnosis, patients
with data*
I and II† 51 of 598 (9) 52 of 597 (9) 57 of 680 (8) 31 of 399 (8) 15 of 116 (13)
III and IV 547 of 598 (91) 545 of 597 (91) 623 of 680 (92) 368 of 399 (92) 101 of 116 (87)
FLIPI
Low (0-1) 127 (21) 125 (21) 149 (22) 75 (19) 28 (24)
Intermediate (2) 225 (37) 223 (37) 263 (38) 137 (34) 48 (41)
High ($ 3) 249 (41) 253 (42) 274 (40) 187 (47) 41 (35)
Bone marrow involvement, patients with
data
318 of 592 (54) 295 of 598 (49) 354 of 676 (52) 197 of 397 (50) 62 of 117 (53)
Extranodal involvement‡ 392 (65) 396 (66) 460 (67) 251 (63) 77 (66)
Bulky disease ($ 7 cm), patients with data 255 of 600 (43) 271 of 600 (45) 274 of 686 (40) 206 of 398 (52) 46 of 116 (40)
Time from initial diagnosis to random
assignment, months
1.5 (0.1-121.6) 1.4 (0.0-168.1) 1.5 (0.1-103.5) 1.4 (0-168.1) 1.2 (0.2-86.4)
Charlson Comorbidity Index score $ 1§ 114 (19) 140 (23) 163 (24) 69 (17) 22 (19)
NOTE. Data are No. (%) or median (range).
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; FLIPI, Follicular Lymphoma
International Prognostic Index.
*Revisions of Ann Arbor stage (two patients) and FLIPI group (one patient) were made since the primary analysis (updates to database).
†Eighteen patients in this group (obinutuzumab arm, 10; rituximab arm, eight) were randomly assigned to study treatment after being assessed as stage II or above by
the investigators (so meeting study eligibility criteria) but were reassessed as stage I after medical review, and so classiﬁed as protocol violations.
‡Patients with bone marrow involvement were classiﬁed as having extranodal disease.
§Scored retrospectively on the basis of conditions reported on medical history page of case report form.
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Baseline patient and disease characteristics by treatment arm
were reported in the primary paper9; updated data are shown in
Table 1 and the Data Supplement. Comparing baseline data by
allocated chemotherapy showed some notable differences between
groups. Compared with patients assigned to receive bendamustine
and CVP, relatively more patients assigned to receive CHOP (47%)
were in the FLIPI high-risk group (bendamustine, 40%; CVP,
35%), and relatively more had bulky disease (52% v 40% and 40%,
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Fig 2. Kaplan-Meier plots of progression-free survival (PFS) in all patients with follicular lymphoma assessed by (A) investigator, and (B) independent review committee.
(C-E) Investigator-assessed PFS by chemotherapy group: (C) bendamustine; (D) cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); (E) cyclophos-
phamide, vincristine, and prednisone (CVP). G-benda, obinutuzumab plus bendamustine; G-chemotherapy, obinutuzumab plus chemotherapy; R-benda, rituximab plus
bendamustine; R-chemotherapy, rituximab plus chemotherapy.
2398 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Hiddemann et al
Downloaded from ascopubs.org by 138.246.2.190 on February 28, 2020 from 138.246.002.190
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
respectively); comorbidities were more common in the bend-
amustine group (24%with CCI score$ 1 v 17% [CHOP] and 19%
[CVP]), and relatively fewer patients in the CHOP group (1%)
were age $ 80 years than in the other groups (3%, bendamustine;
3%, CVP; Table 1).
Efficacy
After a median follow-up of 41.1 months, investigator-
assessed PFS in all patients with FL was signiﬁcantly longer in
the G plus chemotherapy arm (HR, 0.68; 95% CI, 0.54 to 0.87; P =
.0016), as was IRC-assessed PFS (HR, 0.72; 95% CI, 0.56 to 0.93;
P = .012; Fig 2 and Table 2). The beneﬁt of G over R was seen with
all three chemotherapy backbones (interaction test P = .75) with
HRs for investigator-assessed PFS of 0.63 (95%CI, 0.46 to 0.88) for
bendamustine, 0.72 (0.48 to 1.10) for CHOP, and 0.79 (0.42 to
1.47) for CVP. In addition, 3-year PFS rates were higher for G plus
chemotherapy than R plus chemotherapy (Fig 2 and Table 2). For
all three chemotherapy backbones, TTNALT was longer with G
plus chemotherapy, with no evidence of interaction (P = .48),
although the observed beneﬁt was lower for the CHOP backbone
than for the other backbones (Table 3; Data Supplement). Re-
sponse rates at EOI as assessed by computed tomography scan plus
PET scan showed no signiﬁcant differences between G and R for
any of the chemotherapy backbones (Table 3).
OS data remain immature: 43 (7%, G plus chemotherapy) and
52 (9%, R plus chemotherapy) patients died, resulting in an HR for
OS of 0.82 (95% CI, 0.54 to 1.22; P = .32; Table 2). The frequency
of deaths was higher in patients treated with bendamustine (10%;
66 of 686) than in patients treated with CHOP (5%; 20 of 399) or
CVP (8%; nine of 117).
Safety
Overall safety results were in line with the results of the
primary analysis, with more patients receiving G plus chemotherapy
Table 2. Summary of Efﬁcacy Results (follicular lymphoma intention-to-treat population)
End Point Obinutuzumab Plus Chemotherapy (n = 601) Rituximab Plus Chemotherapy (n = 601)
Observation time, months, median (range) 41.1 (0-61.1)* 41.0 (0.1-61.8)
Investigator-assessed PFS
Events 120 (20) 161 (27)
Estimated 3-year PFS, % (95% CL) 82 (78, 85) 75 (71, 78)
HR (95% CL) 0.68 (0.54, 0.87)
Stratiﬁed log-rank P value† .0016
IRC-assessed PFS
Events 108 (18) 141 (23)
Estimated 3-year PFS, % (95% CL) 83 (80, 86) 79 (75, 82)
HR (95% CL) 0.72 (0.56, 0.93)
Stratiﬁed log-rank P value† .012
Treatment response (CT plus PET scan) at end of induction, investigator
assessed according to 2007 revised response criteria10
CR or PR 254 of 297 (86) 242 of 298 (81)
Percentage difference (95% CL), stratiﬁed 4.3 (21.8, 10.5)
Stratiﬁed P value, Cochran-Mantel-Haenszel test† .17
CR 184 of 297 (62) 169 of 298 (57)
Percentage difference (95% CL), stratiﬁed 5.2 (22.8, 13.3)
Stratiﬁed P value, Cochran-Mantel-Haenszel test† .32
Treatment response (CT plus PET scan) at end of induction,
assessed by IRC according to Lugano 2014 criteria11
CMR or PMR 248 of 297 (84) 234 of 298 (79)
Percentage difference (95% CL) 5.0 (21.5, 11.5)
Stratiﬁed P value, Cochran-Mantel-Haenszel test† .30
CMR 232 of 297 (78) 217 of 298 (73)
Percentage difference (95% CL) 5.3 (21.8, 12.4)
Stratiﬁed P value, Cochran-Mantel-Haenszel test† .18
Time to start of new antilymphoma treatment
Events 86 (14) 120 (20)
Estimated 3-year TTNT, % (95% CL) 87 (84, 90) 81 (78, 84)
HR (95% CL) 0.68 (0.52, 0.90)
Stratiﬁed log-rank P value† .007
Overall survival
Events 43 (7) 52 (9)
Estimated proportion alive at 3 years, % (95% CL) 94 (92, 96) 92 (90, 94)
HR (95% CL) 0.82 (0.54, 1.22)
Stratiﬁed log-rank P value† .32
NOTE. Data are No. (%) unless otherwise shown.
Abbreviations: CL, conﬁdence limits; CMR, completemetabolic response; CR, complete response; CT, computed tomography; FLIPI, Follicular Lymphoma International
Prognostic Index; HR, hazard ratio; IRC, independent review committee; PET, positron emission tomography; PFS, progression-free survival; PMR, partial metabolic
response; PR, partial response; TTNT, time to next treatment.
*Observation time of 0 months corresponds to patients who were lost to follow up immediately after enrolment, with no additional follow up obtained in the updated
analysis.
†Stratiﬁed for FLIPI and chemotherapy regimen.
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(449 of 595; 75%) than R plus chemotherapy (409 of 597;
69%) having grade 3 to 5 AEs. The most common grade 3 to 5
AEs in both treatment arms were cytopenias (particularly neu-
tropenia), infusion-related reactions, and pneumonia (Table 4;
Data Supplement). Substantial differences were observed, how-
ever, between the chemotherapy backbones, with more pro-
nounced differences between treatment arms in the frequency of
grade 3 to 5 AEs and serious AEs in patients treated with CHOP
and CVP than in patients treated with bendamustine. In addition,
the proportion of fatal AEs occurring in patients who had not
previously started new anticancer treatment was higher with
bendamustine treatment (4%) than with CHOP (2%) or CVP
(2%; Table 4).
In an additional six patients treated with bendamustines
(G plus chemotherapy arm, n = 4; R plus chemotherapy arm,
n = 2), fatal AEs occurred after patients had started new
systemic anticancer treatment either for disease progression
(n = 4) or new malignancies (n = 2); in ﬁve of the six patients,
the fatal event was an infection. Fifteen of 39 patients with
fatal AEs that occurred before new anticancer treatment
(bendamustine, 14; CHOP, one) either had a CCI score$ 1, or
were $ 80 years of age, or had Eastern Cooperative Oncology
Group performance status of 2; an additional ﬁve patients
(bendamustine, n = 4; CVP, n = 1) had more than one of these
risk factors (Data Supplement). In patients age $ 70 years at
enrollment, fatal events that occurred before new anticancer
treatment were more common with bendamustine (16 of 119,
13%) than CHOP (one of 55, 2%) and CVP (one of 25, 4%),
whereas in patients younger than 70 years of age, the incidence
was similar (14 of 557, 3%; six of 341, 2%; and one of 92, 1%,
respectively).
The frequency of all grade 3 to 5 AEs was higher in patients
treated with CHOP than in patients treated with bendamustine and
CVP, driven by the higher frequency of cytopenias in the CHOP
group. Grade 3 to 5 infections, however, occurred more frequently
in the patients treated with bendamustine (Table 4), a difference
that was driven by higher rates of events during the maintenance
phase (Data Supplement).
Table 3. Summary of Efﬁcacy Results by Chemotherapy Regimen (follicular lymphoma intention-to-treat population)
End Point
Bendamustine CHOP CVP
Obinutuzumab
(n = 345)
Rituximab
(n = 341)
Obinutuzumab
(n = 196)
Rituximab
(n = 203)
Obinutuzumab
(n = 60)
Rituximab
(n = 57)
Investigator-assessed PFS
Events 60 (17) 88 (26) 39 (20) 53 (26) 21 (35) 20 (35)
Estimated 3-year PFS, % (95% CL) 84 (79, 88) 76 (71, 81) 81 (74, 86) 76 (68, 81) 71 (57, 81) 64 (49, 76)
HR (95% CL) 0.63 (0.46, 0.88) 0.72 (0.48, 1.10) 0.79 (0.42, 1.47)
Stratiﬁed log-rank P value* .0062 .13 .46
IRC-assessed PFS
Events 58 (17) 79 (23) 37 (19) 47 (23) 13 (22) 15 (26)
Estimated 3-year PFS, % (95% CL) 85 (81, 89) 81 (76, 85) 82 (75, 87) 77 (70, 82) 77 (63, 86) 77 (63, 86)
HR (95% CL) 0.67 (0.48, 0.94) 0.83 (0.54, 1.28) 0.70 (0.33, 1.49)
Stratiﬁed log-rank P value* .02 .40 .35
Time to new antilymphoma treatment
Events 47 (14) 72 (21) 28 (14) 33 (16) 11 (18) 15 (26)
Estimated proportion not started new treatment at
3 years, % (95% CL)
87 (83, 91) 80 (75, 84) 87 (82, 91) 85 (80, 90) 87 (75, 93) 74 (61, 84)
HR (95% CL) 0.62 (0.43, 0.89) 0.89 (0.54, 1.47) 0.60 (0.27, 1.30)
Stratiﬁed log-rank P value* .009 .65 .19
Treatment response (CT plus PET scan)
at end of induction, investigator
assessed according to 2007 revised
response criteria10
CR or PR 148 of 173 (86) 131 of 165 (79) 91 of 103 (88) 91 of 103 (88) 15 of 21 (71) 20 of 30 (67)
Percentage difference (95% CL) 6.2 (22.3, 14.6) 0.0 (29.3, 9.3) 4.8 (223.8, 33.3)
Stratiﬁed P value, Cochran-Mantel-Haenszel test* .11 .98 .72
CR 109 of 173 (63) 100 of 165 (61) 68 of 103 (66) 63 of 103 (61) 7 of 21 (33) 6 of 30 (20)
Percentage difference (95% CL) 2.4 (28.3, 13.1) 4.9 (28.8, 18.5) 13.3 (214.3, 41.0)
Stratiﬁed P value, Cochran-Mantel-Haenszel test* .63 .52 .36
Treatment response (CT plus PET scan) at end
of induction, assessed by IRC according
to Lugano 2014 criteria11
CMR or PMR 149 of 173 (86) 137 of 165 (83) 85 of 103 (83) 80 of 103 (78) 16 of 21 (76) 19 of 30 (63)
Percentage difference (95% CL) 3.1 (24.9, 11.1) 4.9 (26.6, 16.3) 12.9 (215.1, 40.9)
Stratiﬁed P value, Cochran-Mantel-Haenszel test* .38 .35 .40
CMR 144 of 173 (83) 127 of 165 (77) 76 of 103 (74) 71 of 103 (69) 14 of 21 (67) 18 of 30 (60)
Percentage difference (95% CL) 6.3 (22.6, 15.1) 4.9 (8.0, 17.7) 6.7 (223.0, 36.3)
Stratiﬁed P value, Cochran-Mantel-Haenszel test* .13 .44 .80
NOTE. Data are No. (%) unless otherwise shown.
Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CL, conﬁdence limits; CMR, completemetabolic response; CR, complete response;
CT, computed tomography; CVP, cyclophosphamide, vincristine, and prednisone; FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; IRC,
independent review committee; PET, positron emission tomography; PFS, progression-free survival; PMR, partial metabolic response; PR, partial response.
*Stratiﬁed for FLIPI and chemotherapy regimen.
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Grade 3 and 4 neutropenia (for both treatment arms) was
most common in patients treated with CHOP, particularly during
induction (Data Supplement), and occurred more frequently with
G than R in patients treated with CHOP and CVP, but not in
patients treated with bendamustine. Prophylactic use of colony-
stimulating factors at any time was more frequent in patients
treated with CHOP (56%) than patients treated with bend-
amustine (15%) or CVP (20%). Anti-infective prophylaxis was also
used more frequently in patients treated with CHOP (Data Sup-
plement). The frequency of grade 3 to 5 second neoplasms was
slightly higher in patients treated with bendamustine than other
patients, the difference being driven mainly by nonmelanoma skin
cancers (Table 4; Data Supplement).
In patients treated with bendamustine, marked reductions in
CD3+ and CD3+CD4+ T cells were seen during induction in both
antibody arms, with prolonged recovery during and after main-
tenance; changes in T-cell counts in patients treated with CHOP
and CVP were negligible (Figs 3A-3C). Over the whole study
period, reductions from baseline in IgA, IgG, and IgM levels were
similar in both antibody arms, with little difference among the
three chemotherapy regimens (Data Supplement).
DISCUSSION
On the basis of this updated analysis of previously untreated
patients with advanced-stage FL in the GALLIUM study, which
conﬁrmed the superiority of G over R when combined with either
bendamustine, CHOP, or CVP chemotherapy for induction fol-
lowed by 2 years of antibody-only maintenance, there were notable
differences among the three chemotherapy backbones. Patient al-
location to chemotherapy was not random, resulting in differences
in baseline characteristics among chemotherapy groups, with more
patients with bulky disease and high-risk FLIPI in the CHOP-
assigned group, and older age and higher comorbidity index in
the bendamustine-assigned group. Nonetheless, several interesting
results emerged. The use of G prolonged PFS in all three chemo-
therapy groups. Although the beneﬁt of G over R, as shown by
Kaplan-Meier curves for TTNALT, seemed less pronounced in the
CHOP group, this might have been due to inadequate statistical
power to detect treatment differences for any of the chemotherapy
regimens, and an interaction test provided no statistical evidence
that the treatment effect on TTNALTwas affected by chemotherapy.
Table 4. Summary of Adverse Events in the FL Safety Population by Treatment Arm and Chemotherapy Regimen
Patients Reporting $ 1 AE
G Plus Bendamustine
(n = 338)
R Plus Bendamustine
(n = 338)
G Plus
CHOP
(n = 193)
R Plus
CHOP
(n = 203)
G Plus
CVP
(n = 61)
R Plus
CVP
(n = 56)
G Plus
Chemotherapy
(n = 595)
R Plus
Chemotherapy
(n = 597)
AEs (any grade) 338 (100) 331 (98) 191 (99) 201 (99) 61 (100) 56 (100) 593 (100) 585 (98)
Grade 3-5 AEs 233 (69) 228 (67) 171 (89) 151 (74) 42 (69) 30 (54) 449 (75) 409 (69)
Neutropenia 100 (30) 102 (30) 137 (71) 111 (55) 28 (46) 13 (23) 265 (45) 226 (38)
Leucopenia 11 (3) 15 (4) 39 (20) 34 (17) 1 (2) 1 (2) 51 (9) 50 (8)
Febrile neutropenia 18 (5) 13 (4) 22 (11) 14 (7) 2 (3) 2 (4) 42 (7) 29 (5)
Infusion-related reactions 18 (5) 10 (3) 17 (9) 9 (4) 2 (3) 3 (5) 40 (7) 22 (4)
Pneumonia 23 (7) 17 (5) 5 (3) 8 (4) 0 4 (7) 28 (5) 29 (5)
Thrombocytopenia 20 (6) 11 (3) 15 (8) 5 (2) 1 (2) 0 36 (6) 16 (3)
Anemia 8 (2) 5 (1) 15 (8) 8 (4) 1 (2) 0 24 (4) 13 (2)
Dyspnea 6 (2) 3 (1) 8 (4) 3 (1) 2 (3) 3 (5) 17 (3) 9 (2)
Serious AEs 176 (52) 160 (47) 76 (39) 67 (33) 26 (43) 19 (34) 281 (47) 246 (41)
Deaths* 28 (8) 37 (11) 11 (6) 9 (4) 3 (5) 6 (11) 42 (7) 52 (9)
Fatal AEs 20 (6) 16 (5) 3 (2) 4 (2) 1 (2) 1 (2) 24 (4) 21 (4)
Fatal AEs occurring before start of
NACT
16 (5) 14 (4) 3 (2) 4 (2) 1 (2) 1 (2) 20 (3) 19 (3)
AEs causing treatment
discontinuation
52 (15) 48 (14) 32 (17) 31 (15) 11 (18) 9 (16) 98 (16) 88 (15)
Selected AE categories of special
interest (grade 3-5)
Neutropenia† 107 (32) 107 (32) 142 (74) 115 (57) 29 (48) 14 (25) 278 (47) 236 (40)
Infections‡ 89 (26) 66 (20) 23 (12) 25 (12) 8 (13) 7 (13) 121 (20) 98 (16)
Opportunistic infections, including
herpes zoster§
10 (3) 6 (2) 5 (3) 2 (1) 0 0 15 (3) 8 (1)
Second neoplasms|| 21 (6) 12 (4) 7 (4) 7 (3) 1 (2) 2 (4) 29 (5) 21 (4)
Nonmelanoma skin cancer 7 (2) 3 (1) 0 0 1 (2) 0 8 (1) 3 (1)
Hematologic tumors¶ 3 (1) 0 3 (2) 0 0 0 6 (1) 0
Other solid tumors 11 (3) 9 (3) 4 (2) 7 (3) 0 2 (4) 15 (3) 18 (3)
Cardiac events# 13 (4) 12 (4) 6 (3) 5 (2) 4 (7) 0 23 (4) 17 (3)
NOTE. Data presented as No. (%). Grade$ 3 adverse event preferred terms are thosewith frequency of$ 5% for any antibody plus chemotherapy combination shown.
Abbreviations: AE, adverse event; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; FL,
follicular lymphoma; G, obinutuzumab; NACT, new anticancer therapy; R, rituximab.
*One additional patient died (randomly assigned to G plus bendamustine) but was excluded from the FL safety population because they did not receive any study drug;
this patient was included in the FL intention-to-treat population.
†Neutropenia and associated complications reported as AEs (not based on laboratory values).
‡Any adverse event in system organ class Infections and Infestations.
§Fungal infections, cytomegalovirus, herpes zoster, and Pneumocystis jirovecii pneumonia.
||Malignant or unspeciﬁed tumors occurring . 6 months after ﬁrst study drug intake (standardized Medical Dictionary for Regulated Activities query).
¶Hodgkin disease (n = 3), acute myeloid leukemia (n = 2), and acute lymphocytic leukemia (n = 1).
#Any adverse event in system organ class Cardiac Disorders.
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Fig 3. T-cell counts over time by treatment arm and chemotherapy regimen: (A) CD3+ cells; (B) CD3+CD4+ and CD3+CD8+ cells. Horizontal gray lines are upper and lower
limits of normal range. BL, baseline; C, cycle; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; D,
day; EOI, end of induction; G-chemotherapy, obinutuzumab plus chemotherapy; Mo, month; R-chemotherapy, rituximab plus chemotherapy.
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Three-year PFS rates were highest in the bendamustine group
and lowest in the CVP group, suggesting that CVP was the least
efﬁcacious partner. This ﬁnding is consistent with the latest results
of the randomized FOLL-05 study of R plus chemotherapy in
patients with FL, whose authors reported 8-year PFS rates of 46%
for CVP and 57% for CHOP.8 Two other studies showed bend-
amustine to be a more efﬁcacious partner for R: ﬁrst, the phase III
trial by Study Group Indolent Lymphomas (StiL), which compared
R plus bendamustine with R plus CHOP in a subgroup of patients
with FL, with surprisingly poor PFS results for R-CHOP; and
second, the BRIGHT study, which found that PFS was longer with
R plus bendamustine than with R plus CHOPor CVP.6,7 Both trials
included patients with nonfollicular histology, and neither in-
cluded a maintenance phase.
The most interesting and clinically relevant data from the
current analysis, however, relate to AEs. As previously reported,
grade 3 to 5 AEs were more common with G plus chemotherapy
than with R plus chemotherapy, with higher rates of neutropenia,
infections, infusion-related reactions, and thrombocytopenia.9
Analysis by chemotherapy backbone revealed a higher frequency
of grade 3 to 5 AEs with G plus chemotherapy in patients receiving
CHOPor CVP but not in patients receiving bendamustine. Overall,
grade 3 to 5 events were more frequent in patients treated with
CHOP than patients treated with bendamustine or CVP, primarily
because of a higher rate of cytopenias. For grade 3 to 5 infections,
however, the frequency was higher with bendamustine than with
CHOP or CVP in both the G and R treatment arms; this difference
was particularly evident during the maintenance and follow-up
phases. A possible explanation for this ﬁnding may be the sub-
stantial and long-lasting suppression of CD3+ and CD3+CD4+
T cells in the bendamustine group. Similar ﬁndings were reported
in heavily pretreated patients with indolent lymphomas who re-
ceived R plus bendamustine.13 A sustained decrease in CD4+ and
CD8+ T-cell counts after ﬁrst-line treatment of indolent lym-
phomas with R plus bendamustine was also described by Burchardt
et al,14 although infectious complications did not increase. Severe
lymphocyte count reductions were more common with bend-
amustine than CHOP when used with R in the BRIGHT study,
although severe neutropenia was more frequent with CHOP.4 In
line with the BRIGHT results and the current GALLIUM analysis,
the StiL trial also found that serious cytopenias were more
common with R plus CHOP than with R plus bendamustine for
patients with previously untreated indolent NHL, but infections
were also found to be more frequent in the CHOP group.5 This
contrasts with our results, although it should be noted that pro-
phylaxis with colony-stimulating factors in GALLIUM was used
more frequently in patients treated with CHOP than in patients
treated with bendamustine.
Fatal AEs were more common with bendamustine than
with CHOP or CVP. This difference in safety proﬁle was not
reported in previous studies and may be attributable to the
nonrandomized allocation to chemotherapy in GALLIUM, so
relatively more patients in the bendamustine group were $ 80
years of age, had poor performance status, and/or had
comorbidities. In addition, AE monitoring and follow-up was
probably more rigorous in GALLIUM. The higher incidence of
second neoplasms in patients treated with bendamustine was
primarily driven by a higher incidence of nonmelanoma skin
cancers.
Although GALLIUM was not designed to detect signiﬁcant
differences between antibody arms at the chemotherapy backbone
level, and such a comparison is confounded by imbalances in
baseline characteristics due to the nonrandomized selection of
chemotherapy, our results demonstrate that the efﬁcacy beneﬁts of
G persisted with all three chemotherapy backbones. Safety proﬁles
differed, however, with cytopenias being more common with
CHOP and severe infections more common with bendamustine.
Fatal AEs were also more common with bendamustine, although
this ﬁnding was probably confounded by age, comorbidities, and
initiation of new anticancer therapy. The nature of AEs in patients
with FL in GALLIUM in this analysis was consistent with the
known safety proﬁles of the study treatments. Hence, although G
can be considered as the new standard anti-CD20 antibody for
ﬁrst-line therapy of FL, the most appropriate chemotherapy
partner should be selected with care, taking individual patient
characteristics and risk proﬁles into consideration.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Wolfgang Hiddemann, Michael Herold, Gu¨nter
Fingerle-Rowson, Robert E. Marcus
Provision of study materials or patients: Kensei Tobinai
Collection and assembly of data: Wolfgang Hiddemann, Anna Maria
Barbui, Miguel A. Canales, Graham P. Collins, Jan Du¨rig, Roswitha
Forstpointner, Michael Herold, John F. Seymour, Kensei Tobinai, Gu¨nter
Fingerle-Rowson
Data analysis and interpretation:Wolfgang Hiddemann, Paul K. Cannell,
Michael Herold,MarkHertzberg,MagdalenaKlanova, JohnRadford, John F.
Seymour, Kensei Tobinai, Judith Trotman, Alis Burciu, Gu¨nter Fingerle-
Rowson, Marcel Wolbers, Tina Nielsen, Robert E. Marcus
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
REFERENCES
1. Salles G, Seymour JF, Feugier P, et al: Long term
follow-up of the PRIMA study: half of patients receiving
rituximab maintenance remain progression free at 10
years [abstract]. Blood 130:486, 2017 (suppl 1)
2. Hiddemann W, Kneba M, Dreyling M, et al:
Frontline therapy with rituximab added to the com-
bination of cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) signiﬁcantly improves
the outcome for patients with advanced-stage fol-
licular lymphoma compared with therapy with CHOP
alone: Results of a prospective randomized study of
the German Low-Grade Lymphoma Study Group.
Blood 106:3725-3732, 2005
3. Marcus R, Imrie K, Solal-Celigny P, et al: Phase
III study of R-CVP comparedwith cyclophosphamide,
vincristine, and prednisone alone in patients with
previously untreated advanced follicular lymphoma.
J Clin Oncol 26:4579-4586, 2008
jco.org © 2018 by American Society of Clinical Oncology 2403
Obinutuzumab in First-Line FL: Analysis by Chemotherapy Regimen
Downloaded from ascopubs.org by 138.246.2.190 on February 28, 2020 from 138.246.002.190
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
4. Flinn IW, van der Jagt R, Kahl BS, et al: Ran-
domized trial of bendamustine-rituximab or R-CHOP/
R-CVP in ﬁrst-line treatment of indolent NHL or MCL:
The BRIGHT study. Blood 123:2944-2952, 2014
5. Rummel MJ, Niederle N, Maschmeyer G,
et al: Bendamustine plus rituximab versus CHOP plus
rituximab as ﬁrst-line treatment for patients with in-
dolent and mantle-cell lymphomas: An open-label,
multicentre, randomised, phase 3 non-inferiority trial.
Lancet 381:1203-1210, 2013
6. Rummel MJ, Maschmeyer G, Ganser A, et al:
Bendamustine plus rituximab (B-R) versus CHOP
plus rituximab (CHOP-R) as ﬁrst-line treatment in
patients with indolent lymphomas: nine-year updated
results from the StiL NHL1 study [abstract]. J Clin
Oncol 35: 7501, 2017 (suppl 15)
7. Flinn IW, van der Jagt R, Chang JE, et al: First-
line treatment of iNHL or MCL patients with BR
or R-CHOP/R-CVP: Results of the BRIGHT 5-year
follow-up study [abstract]. J Clin Oncol 35:7500, 2017
(suppl 15)
8. Luminari S, Tarantino V, Anastasia A, et al:
Long term results of the FOLL05 randomized study
comparing R-CVP with R-CHOP and R-FM as ﬁrst line
therapy in patients with advanced stage follicular
lymphoma: A FIL study. Hematol Oncol 35:34, 2017
(suppl S2)
9. Marcus R, Davies A, Ando K, et al: Obinutu-
zumab for the ﬁrst-line treatment of follicular lym-
phoma. N Engl J Med 377:1331-1344, 2017
10. Cheson BD, Pﬁstner B, Juweid ME, et al:
Revised response criteria for malignant lymphoma.
J Clin Oncol 25:579-586, 2007
11. Cheson BD, Fisher RI, Barrington SF, et al:
Recommendations for initial evaluation, staging, and
response assessment of Hodgkin and non-Hodgkin
lymphoma: The Lugano classiﬁcation. J Clin Oncol
32:3059-3068, 2014
12. Moher D, Hopewell S, Schulz KF, et al:
CONSORT 2010 explanation and elaboration: Upda-
ted guidelines for reporting parallel group randomised
trials. BMJ 340:c869, 2010
13. Ito K, Okamoto M, Ando M, et al: Inﬂuence
of rituximab plus bendamustine chemotherapy
on the immune system in patients with refrac-
tory or relapsed follicular lymphoma and mantle
cell lymphoma. Leuk Lymphoma 56:1123-1125,
2015
14. Burchardt A, Barth J, Rummel MJ, et al:
Immunochemotherapywith bendamustine-rituximab
(BR) as induction therapy for indolent lymphomas
results in a severe lymphopenia with low CD4 + and
CD8 + counts without an increase in atypical in-
fections. First results of the infectious disease (ID)
project of a prospective, randomized, multicentre
study (STIL NHL 7-2008) [abstract]. Hematol Oncol
31:032 2013 (suppl 1)
Affiliations
Wolfgang Hiddemann and Roswitha Forstpointner, University Hospital, Ludwig Maximilian University Munich, Munich; Jan
Du¨rig, University Hospital Essen, Essen; Michael Herold, HELIOS-Klinikum Erfurt, Erfurt, Germany; Anna Maria Barbui, Azienda
Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;Miguel A. Canales, Hospital Universitario la Paz, Madrid, Spain; Paul K. Cannell, Fiona
Stanley Hospital, Murdoch,Western Australia;MarkHertzberg, Prince ofWales Hospital; Judith Trotman, Concord Repatriation General
Hospital, University of Sydney, Sydney, New South Wales; John F. Seymour, Royal Melbourne Hospital, and University of Melbourne,
Melbourne, Victoria, Australia; Graham P. Collins, Churchill Hospital, Oxford; John Radford, University of Manchester and the Christie
National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester; Robert E. Marcus, Kings College
Hospital, London, United Kingdom; Magdalena Klanova, Charles University General Hospital, Prague, Czech Republic; Magdalena
Klanova, Alis Burciu, Gu¨nter Fingerle-Rowson, Marcel Wolbers, and Tina Nielsen, F. Hoffmann-La Roche, Basel, Switzerland; and
Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan.
Support
GALLIUM was sponsored by F. Hoffmann-La Roche. G.P.C. was supported by the Blood Theme of the Oxford National Institute for
Health Research Biomedical Research Centre. Third-party medical writing assistance was funded by F. Hoffmann-La Roche.
Prior Presentation
Presented in part at the 14th International Conference onMalignant Lymphoma, Lugano, Switzerland, June 14-17, 2017; and the 22nd
Congress of the European Hematology Association, Madrid, Spain, June 22-25, 2017.
n n n
2404 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Hiddemann et al
Downloaded from ascopubs.org by 138.246.2.190 on February 28, 2020 from 138.246.002.190
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Inﬂuence of
Chemotherapy on Efﬁcacy and Safety
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Wolfgang Hiddemann
Honoraria: Roche, Janssen, Celgene
Consulting or Advisory Role: Roche, Janssen, Celgene
Research Funding: Roche, Janssen, Celgene
Anna Maria Barbui
No relationship to disclose
Miguel A. Canales
Consulting or Advisory Role: Roche, Celgene, Janssen, Gilead Sciences
Paul K. Cannell
No relationship to disclose
Graham P. Collins
Honoraria: Roche, Takeda, Gilead Sciences, Celleron Therapeutics, MSD
Oncology, Bristol-Myers Squibb
Consulting or Advisory Role: Takeda, Roche, Celleron Therapeutics,
MSD Oncology, Gilead Sciences, Bristol-Myers Squibb
Speakers’ Bureau: Roche, Takeda
Research Funding: Amgen (Inst), Celgene (Inst), MSD Oncology (Inst),
Celleron Therapeutics
Travel, Accommodations, Expenses: Takeda, Roche
Jan Du¨rig
Consulting or Advisory Role: Roche
Speakers’ Bureau: Roche
Roswitha Forstpointner
No relationship to disclose
Michael Herold
Consulting or Advisory Role: Roche
Speakers’ Bureau: Roche
Research Funding: Roche
Mark Hertzberg
Consulting or Advisory Role: Roche, Takeda, MSD, Janssen
Magdalena Klanova
Employment: Roche
John Radford
Stock or Other Ownership: AstraZeneca (I), GlaxoSmithKline (I)
Consulting or Advisory Role: Novartis, Takeda
Speakers’ Bureau: Takeda, Seattle Genetics, Bristol-Myers Squibb,
Novartis
Research Funding: Takeda
Travel, Accommodations, Expenses: Takeda, Bristol-Myers Squibb
John F. Seymour
Honoraria: AbbVie, Celgene, Genentech, Gilead Sciences, Janssen, Roche,
Takeda
Consulting or Advisory Role: AbbVie, Celgene, Genentech, Gilead
Sciences, Janssen, Roche, Takeda
Research Funding: AbbVie
Travel, Accommodations, Expenses: Roche
Kensei Tobinai
Honoraria: Zenyaku Kogyo, Eisai, Takeda, Mundipharma, Janssen, HUYA
Bioscience International, Kyowa Hakko Kirin, Celgene, Chugai
Pharmaceutical, Ono Pharmaceutical
Consulting or Advisory Role: Celgene, Zenyaku Kogyo, HUYA Bioscience
International
Research Funding: Chugai Pharmaceutical (Inst), Kyowa Hakko Kirin
(Inst), Ono Pharmaceutical (Inst), Celgene (Inst), Janssen (Inst),
GlaxoSmithKline (Inst), Eisai (Inst), Mundipharma (Inst), Takeda (Inst),
SERVIER (Inst), AbbVie (Inst)
Judith Trotman
Research Funding: Roche (Inst), BeiGene (Inst), Janssen (Inst),
Pharmacyclics (Inst), Celgene (Inst)
Travel, Accommodations, Expenses: Roche
Alis Burciu
Employment: Roche, Roche (I), Novartis
Stock or Other Ownership: Roche, Roche (I), Novartis
Gu¨nter Fingerle-Rowson
Employment: Roche
Stock or Other Ownership: Roche
Marcel Wolbers
Employment: Roche
Consulting or Advisory Role: Roche
Tina Nielsen
Employment: Roche
Stock or Other Ownership: F. Hoffmann-La Roche
Robert E. Marcus
Honoraria: Roche, Gilead Sciences
Consulting or Advisory Role: Roche, Gilead Sciences
Speakers’ Bureau: Roche
Travel, Accommodations, Expenses: Roche
jco.org © 2018 by American Society of Clinical Oncology
Obinutuzumab in First-Line FL: Analysis by Chemotherapy Regimen
Downloaded from ascopubs.org by 138.246.2.190 on February 28, 2020 from 138.246.002.190
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
Acknowledgment
We thank all patients, investigators, and study team members. We also thank the following Roche employees: Harald Zeuner,
Norodom Campos, Jessica Colman (Clinical Science), Kaspar Ruﬁbach (Biostatistics), Mike Hall (SPA), and Andres Schneider (Safety).
Third-party medical writing assistance, under the direction of Wolfgang Hiddemann, was provided by Roger Nutter and Scott Malkin of
Gardiner-Caldwell Communications and was funded by F. Hoffmann-La Roche.
© 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Hiddemann et al
Downloaded from ascopubs.org by 138.246.2.190 on February 28, 2020 from 138.246.002.190
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
